Skip to main content
. 2013 Dec 5;8:4659–4671. doi: 10.2147/IJN.S51927

Figure 4.

Figure 4

Micro-SPECT/CT images of U-87 MG tumor-xenografted SCID mice after intravenous injection of 111In-labeled liposomal nanoparticles: (A) RLP, (B) Hybrid-LP, and (C) NoTarget-LP 4 hours after administration; (D) RLP, (E) Hybrid-LP, and (F) NoTarget-LP at 24 hours post-injection (RLP, n=1; Hybrid-LP, n=1; NoTarget-LP, n=1).

Abbreviations: 111In, indium-111; B, bladder; Hybrid-LP, liposomal nanoparticle carrying an RGD and SP building block; I, intestine; L, liver; LP, liposome; NoTarget-LP, liposomal nanoparticle with no targeting sequence; RGD, arginine-glycine-aspartic acid; RLP, liposomal nanoparticle carrying an RGD building block; SCID, severe combined immunodeficiency; SP, substance P; SPECT/CT, single photon emission computed tomography/computed tomography; T, tumor.